The Value of Fecal Microbiota Transplantation in the Treatment of Ulcerative Colitis Patients: A Systematic Review and Meta-Analysis

Table 1

Demographic and clinical features at enrollment in clinical trials.

Source

Year

Country

RCT

No. of enrolled patients (missing)

Age

Severity of UC

Duration time of UC (years)

Concomitant drug treatment

FMT delivery

FMT frequency

Follow-up (months)

Assessment

Angelberger

2013

Austria

No

5

34.2 ± 12.56

Moderately, severely

4.1 ± 3.37

Yes

Nasojejunal tube and enema

Single

3

Mayo scores, CRP, fecal calprotectin

Kahn

2013

Chicago

No

44 (51)

39

Mildly, moderately, severely

7

NA

Colonoscopy (77%, enema (20%), nasogastric tube (3%)

Single

1

NA

Kunde

2013

Atlanta

No

10

15.2 ± 4.44

Mildly, moderately

3.51 ± 2.63

Yes

Enema

Single

2

PUCAI

Patrizia

2013

Austria

No

6

36.5 ± 12.1

NA

5.5 ± 4.32

Yes

Colonoscopy

Single

3

Fecal calprotectin, Mayo scores, CRP

Cui

2015

China

No

15

31.67 ± 10.22

Moderately, severely

4.2 ± 2.91

Yes

Colonoscopy

1 single, 5 twice

3

CRP, ESR

Damman

2015

America

No

7

41.14 ± 15.5

Mildly, moderately

16.57 ± 13.14

Yes

Colonoscopy

Single

NA

DSI, fecal calprotectin, UCDAI

Moayyedi

2015

Canada

Yes

FMT: 36 (2), placebo: 34 (3)

FMT: 42.2 ± 15.0, placebo: 35.8 ± 12.1,

NA

FMT: 7.9 ± 5.6, placebo: 7.0 ± 6.8,

Yes

Enema

6 times

12

Mayo scores, IBDQ, EQ-5D, CRP, ESR

Rossen

2015

Netherlands

Yes

FMT-D: 23, FMT-A: 25

NA

Mildly, moderately

NA

No

Enema

>Single

12

Mayo scores, SCCAI, IBDQ

Suskind

2015

America

No

4

14.5 ± 1.73

Mildly, moderately

1

Yes

Nasogastric tube

Single

3

PUCAI, CRP, stool calprotectin

Laszlo

2016

Romania

No

5

NA

Moderately, severely

3 ± 1

Yes

Colonoscopy

NA

10

NA

Nishida

2016

Japan

No

41 (16)

39.6 ± 16.9

Mildly, moderately

7.6 ± 8.6

Yes

Colonoscopy

Single

2

Mayo scores, CRP

Oprita

2016

Romania

No

5 (28)

NA

Moderately: 1, severely: 4

NA

Yes

Nasojejunal tube (40%), colonoscopy (60%)

Single 1, twice 3

3

NA

Zhang

2016

China

No

19

39.2 ± 14.1

Moderately: 8, severely: 11

8.0 ± 5.8

4 yes, 15 no

Nasogastric tube

Single

3

CRP, cytokines

Wei

2016

China

Yes

FMT: 10, FMT + pectin: 10

FMT: 43.50 ± 15, FMT + pectin: 37.40 ± 9.92

NA

NA

Yes

Colonoscopy

NA

3

Mayo score, ESR, CRP, IBDQ, fecal calprotectin, Shannon index

Ishikawa

2017

Japan

Yes

FMT: 17 (4), AFM: 19 (1)

FMT: 40.4 ± 14.2, AFM: 44.7 ± 14.9

Mildly, severely

FMT: 7.8 ± 8.4, AFM: 7.0 ± 8.0

Yes

Colonoscopy

Single

1

CAI, Mayo scores

Mizuno

2017

Japan

No

10

NA

Moderately: 5, severely: 5

4.5

Yes

Colonoscopy

Single

3

Mayo scores

Vinita

2017

America

No

20

38.4 ± 12.6

NA

NA

Yes

Colonoscopy

Single

3

Mayo scores

Paramsothy

2017

Australia

Yes

FMT: 41(1), placebo: 40(3)

35.6

NA

5.8

Yes

Enema

NA

2

Mayo scores, IBDQ

Note: RCT: randomized controlled trials; NA: not available (NA); AFM: amoxicillin, fosfomycin, and metronidazole; HBI: Harvey–Bradshaw Index; MRI: magnetic resonance imaging; CT: computed tomography scan (CT); ESR: erythrocyte sedimentation rate; CRP: C-reactive protein; PCDAI: pediatric Crohn’s disease activity index; CBC: complete blood count; BCI: Bray–Curtis index; sIBDQ: short inflammatory bowel disease questionnaire; CDEIS: Crohn’s Disease Endoscopic Index of Severity; QoL: quality of life; CDAI: Crohn’s disease activity index; UCCS: Ulcerative Colitis Clinical Score; SES-CD: simplified endoscopic activity score; PUCAI: pediatric UC activity index; EQ-5D: EuroQol; SCCAI: simple clinical colitis activity index; IBDQ inflammatory bowel disease questionnaire. Concomitant drug treatment: infliximab, cyclosporine, thiopurine, methotrexate, steroid, and so on.